ClinicalTrials.gg
CompletedNCT01417078Updated Mar 29, 2017Results posted

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

A Phase 2 interventional study of Diazepam in Epilepsy, sponsored by Acorda Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.

Enrollment
8th of 10
31 · median 68
Started
2011
with 1 other
Phase 2
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Acorda Therapeutics

Among the 10 studies testing diazepam in Epilepsy, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 4th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →

Where they have run

About diazepam

Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing diazepam in Epilepsy as a file.
02

Study summary

The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed for study participation.
  • General good health with no unstable abnormalities.
  • Diagnosis of epilepsy.

Exclusion criteria

Exclusion Criteria:

  • Individuals receiving warfarin (Coumadin®) or dabigatran (Pradaxa®).
  • Use of any drug within 30 days.
  • Blood or plasma donation within 30 days.
  • Not willing or unable to tolerate blood draws.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Diazepam Nasal Spray

    Drug: Diazepam

Interventions

  • single-dose; dosage in mg, based on patient body weight

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax),

    Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Cmax. The mean Cmax value was adjusted to a 20 mg dose.

    Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours

  2. Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax)

    Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Tmax. The mean Tmax value was adjusted to a 20 mg dose.

    Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours

  3. Pharmacokinetic (PK) Parameter: Area Under The Concentration Curve From Time 0 to 12 Hours (AUC(0-12)) and AUC Time to Last Measurable Plasma Concentration

    Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter AUC(0-12) and AUC(last). The mean estimate of AUC(0-12) was adjusted to a 20 mg dose. AUC(last) was used for the calculation of AUC for nordiazepam. AUC(0-12) values could not be estimated for nordiazepam given that nordiazepam concentrations were rising between 6 and 12 hours.

    Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours

Secondary outcomes

  1. Number of Patients With Treatment Emergent Adverse Events (TEAEs)

    TEAEs refer to adverse events with start dates occurring after dosing. Treatment-Related TEAEs refer to those 'possibly' or 'probably' related to study drug. Intensity definitions: * Mild: Usually transient, required no special treatment, and did not interfere with the patient's daily activities. * Moderate: Usually caused a low degree of inconvenience or concern to the patient, and may have interfered with daily activities, but was usually ameliorated by simple therapeutic measures. * Severe: Interrupted a patient's usual daily activities, and generally required systemic drug therapy or other treatment.

    Time frame: Pre-dose to 48 hours post-dose

07

Results

Posted Mar 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneDiazepam Nasal Spray
Started31
Completed30
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax),

Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Cmax. The mean Cmax value was adjusted to a 20 mg dose.

Time frame:
Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Reported as:
Mean · nanogram/milliliter (ng/mL)
Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax),
nanogram/milliliter (ng/mL)Diazepam Nasal SprayNordiazepam
Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax),208 ± 90.323.9 ± 16.5
SecondaryNumber of Patients With Treatment Emergent Adverse Events (TEAEs)

TEAEs refer to adverse events with start dates occurring after dosing. Treatment-Related TEAEs refer to those 'possibly' or 'probably' related to study drug. Intensity definitions: * Mild: Usually transient, required no special treatment, and did not interfere with the patient's daily activities. * Moderate: Usually caused a low degree of inconvenience or concern to the patient, and may have interfered with daily activities, but was usually ameliorated by simple therapeutic measures. * Severe: Interrupted a patient's usual daily activities, and generally required systemic drug therapy or other treatment.

Time frame:
Pre-dose to 48 hours post-dose
Reported as:
Number · participants
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
participantsDiazepam Nasal Spray
Subjects with one or more TEAEs28
Total number of TEAEs96
Subjects with one or more Treatment-Related TEAEs21
Total number of Treatment-Related TEAEs56
Subjects with one or more Severe TEAEs1
Total number of Severe TEAEs1
Total number of Moderate TEAEs24
Total number of Mild TEAEs71
PrimaryPharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax)

Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Tmax. The mean Tmax value was adjusted to a 20 mg dose.

Time frame:
Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Reported as:
Mean · hour (h)
Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax)
hour (h)Diazepam Nasal SprayNordiazepam
Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax)0.98 ± 0.8611.10 ± 2.14
PrimaryPharmacokinetic (PK) Parameter: Area Under The Concentration Curve From Time 0 to 12 Hours (AUC(0-12)) and AUC Time to Last Measurable Plasma Concentration

Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter AUC(0-12) and AUC(last). The mean estimate of AUC(0-12) was adjusted to a 20 mg dose. AUC(last) was used for the calculation of AUC for nordiazepam. AUC(0-12) values could not be estimated for nordiazepam given that nordiazepam concentrations were rising between 6 and 12 hours.

Time frame:
Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Reported as:
Mean · hour*nanogram/milliliter (h*ng/mL)
Pharmacokinetic (PK) Parameter: Area Under The Concentration Curve From Time 0 to 12 Hours (AUC(0-12)) and AUC Time to Last Measurable Plasma Concentration
hour*nanogram/milliliter (h*ng/mL)Diazepam Nasal SprayNordiazepam
AUC(0-12)1227 ± 488NA ± NA
AUC(last)NA ± NA192 ± 148

Adverse events

Collected over Pre-dose to 48 hours post-dose. Non-serious events are listed at a 3.2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diazepam Nasal Spray—0/31 (0%)28/31 (90.3%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventDiazepam Nasal Spray
HeadacheNervous system disorders16/31
DysgeusiaNervous system disorders8/31
Nasal discomfortRespiratory, thoracic and mediastinal disorders7/31
SomnolenceNervous system disorders5/31
RhinorrhoeaRespiratory, thoracic and mediastinal disorders5/31
NauseaGastrointestinal disorders5/31
Lacrimation increasedEye disorders5/31
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/31
Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders4/31
Tongue injuryInjury, poisoning and procedural complications4/31

Baseline characteristics

Safety Population Number (N)=31 Pharmacokinetic Population N=30

Age, Continuous
Age, Continuous(years)Diazepam Nasal Spray
Mean35.2 ± 12.80
Sex: Female, Male
Sex: Female, Male(Participants)Diazepam Nasal Spray
Female18
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diazepam Nasal Spray
Hispanic or Latino3
Not Hispanic or Latino23
Unknown or Not Reported5
Body Mass Index (BMI)
Body Mass Index (BMI)((kg/m^2))Diazepam Nasal Spray
Mean26.3 ± 4.08
08

Study locations

4 sites
  • Barrow Neurology Clinics at St Joseph's Hospital
    Phoenix, Arizona 85013, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 4 years 1 month after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2011
First posted
Aug 16, 2011
Start
Sep 2011
Primary completionActual
Feb 2013
CompletionActual
Mar 2013
Results delay requested
Jan 27, 2014
Results first posted
Mar 29, 2017
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01417078
Responsible party
Sponsor
First posted
Aug 16, 2011
Start date
Sep 2011
Primary completion
Feb 2013
Completion
Mar 2013
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

David P Ward, MD
study director · Neuronex, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion